Document Type

Master's Culminating Experience

Publication Date



Obesity and metabolic side effects such as diabetes mellitus are major concerns in public health. Mentally ill people are a high risk subgroup for obesity and metabolic syndrome because of behavior, non treatment, and medication side effects. In this research, I conducted a retrospective chart review to compare the weight and body mass index of consumers who were prescribed antipsychotic Type 1 or Type 2 medications. The sample was drawn from consumers attending the Consumer Advocacy Model (CAM) program which is an outpatient substance abuse and mental health treatment program in the Wright State University Boonshoft School of Medicine Department of Community Health.

The primary aim of the study was to evaluate this local clinical population and make recommendations in the context of upcoming universal health coverage plan for prescribing antipsychotic medications. This is based on lowering the cost and increasing effectivity of medication use in treatment for this population.

Method: Medical charts of 195 patients seen at the Consumer Advocacy Model (CAM) Urbana, Ohio location were reviewed, and this data was analyzed. A review of other patients ‘subjective experiences were also gathered from the Consumer Health Resource Group, (Consumer Health Reports, 2011).

Results: During a period of four months, 42 patients were prescribed risperidone; 59 were prescribed olanzapine; 53 were prescribed Seroquel; and 46 were prescribed three other antipsychotics. The predominant adverse effects produced by most of the antipsychotic Type 2 drugs consisted of weight gain and sedation.

Conclusion: This data analysis raises awareness that obesity is a major health risk factor with the use of Type 2 antipsychotic drugs. Suggestions for identifying expected weight gain in the consumers as well as addressing negative health consequences of obesity are discussed.